UNSPSC 51184008: Glipalamide

This classification denotes an anti-diabetic agent with the molecular formula C12H15N3O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) W7J490CUHM, chemically known as 4,5-dihydro-5-methyl-n-((4-methylphenyl)sulfonyl)-1h-pyrazole-1-carboxamide but more generally known as glipalamide, which bears US NIH Compound Identifier 65802. European Medicines Agency schedules Glipalamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07926MIG.

UNSPSC 51184008 Glipalamide, a Commodity code, covers generic pharmaceutical products supplied through cooperative purchasing agreements to state and local government facilities. State and local governments buy standardized, multi-source generic medications and over-the-counter products through established wholesaler networks, with vendors required to maintain current Good Manufacturing Practices (cGMP) certification, Drug Supply Chain Security Act (DSCSA) compliance, and contractual relationships with authorized distributors such as AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson Co., LLC. Issuing bodies under this code include state departments of administration and multistate cooperative purchasing alliances administering on behalf of participating member jurisdictions spanning multiple states. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, is the primary recent buyer, consolidating demand across state and local facilities including participating members in Oregon and beyond.

MMCAP issued an RFP (S1070000015802) on January 20, 2026, for generic multi-source pharmaceuticals and OTC products with a response deadline of March 26, 2026. The solicitation requires vendors to provide fixed or flexible pricing (flat price, net price formats, or WAC-minus structures) for identified products with specific National Drug Codes, with evaluation weighted heavily toward price competitiveness (75 percent) alongside administrative compliance, EDI capability, and pricing format adherence. Awarded vendors must maintain commercial general liability insurance of $5,000,000 per occurrence, network security and privacy liability of $2,000,000, and professional liability of $2,000,000, and all products must meet FDA requirements with expiration dates at least one year from manufacture and a minimum six-month shelf life. Contract terms are two years for new responders with optional extensions, and MMCAP reserves the right to make sole, dual, or multi-awards based on therapeutic considerations and member-specific needs. Award amounts are not disclosed; however, vendors must budget for a 3 percent administrative fee on all contract purchases and performance penalties ranging from $200 to $1,500 per violation.